Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models

Archives of Otolaryngology - Head and Neck Surgery

Volumn 134, Issue 7, 2008, Pages 735-742

  Yoo, George H ^a,c   Subramanian, Geetha ^a   Piechocki, Marie P ^a   Ensley, John F ^a,b   Kucuk, Omer ^a,b   Tulunay, Ozlem E ^a   Lonardo, Fulvio ^c   Kim, Harold ^a   Won, Joshua ^a   Stevens, Timothy ^a   Lin, Lio Sheng ^a,d  

^a Department of Otolaryngology Head and Neck Surgery ^*  (United States)

^b Division of Hematology and Oncology   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GROWTH FACTOR; GROWTH FACTOR RECEPTOR;

ADENOSQUAMOUS CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEAD AND NECK CANCER; LUNG CANCER; MICROENVIRONMENT; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PILOT STUDY; PROTEIN EXPRESSION; SALIVARY GLAND CANCER; SEVERE COMBINED IMMUNODEFICIENCY; TOXICITY; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; WOUND HEALING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, MUCOEPIDERMOID; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; INJECTIONS, INTRALESIONAL; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM TRANSPLANTATION; OTORHINOLARYNGOLOGIC NEOPLASMS; PILOT PROJECTS; SALIVARY GLAND NEOPLASMS; TAXOIDS; TUMOR BURDEN; WOUND HEALING;

EID: 48049110529     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.134.7.735     Document Type: Article

References (44)

1. American Cancer Society. Estimated new cancer cases and deaths by sex for all sites, US, 2007 [table]. In: Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007:4.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328(3):184-194.
4. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Inter-group study 0099. J Clin Oncol. 1998;16(4):1310-1317.
5. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92-98.
6. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91(24):2081-2086.
7. Bernier J, Domenge C, Ozsahin M, et al; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-1952.
8. Cooper JS, Pajak TF, Forastiere AA, et al; Radiation Therapy Oncology Group 9501/ Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350 (19):1937-1944.
9. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995;22(2)(suppl 4):3-16.
10. Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer. 2000;1(1):32-40.
11. Belani CP. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol. 2002;29 (3)(suppl 12):4-9.
12. Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol. 2002;29(3)(suppl 12):22-27.
13. Colevas AD, Norris CM, Tishler RB, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 1999;17(11):3503-3511.
14. Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001;19(4): 1096-1104.
15. Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs. February 2001;12(suppl 1):S21-S24.
16. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23(34):8636-8645.
17. Posner MR, Hershock DM, Blajman CR, et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705-1715.
18. Vermorken JB, Remenar E, Van Herpen C, et al. EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-1704.
19. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332(7):429-435.
20. Ragaz J. Comments on kinetics and biology of the residual cancer, and on relevant therapeutic strategies based on these phenomena. Prog Clin Biol Res. 1990; 354B:117-139.
21. Theon AP, Pascoe JR, Galuppo LD, Fisher PE, Griffey SM, Madigan JE. Comparison of perioperative versus postoperative intratumoral administration of cis-platin for treatment of cutaneous sarcoids and squamous cell carcinomas in horses J Am Vet Med Assoc. 1999;215(11):1655-1660.
22. Whitworth MK, Sheen A, Rosa DD, etal. Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. J Cancer Res Clin Oncol. 2006;132(1):41-44.
23. Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992;23(4):705-713
24. Adjuvant chemotherapy for advanced head and neck squamous carcinoma: final report of the Head and Neck Contracts Program. Cancer. 1987;60(3):301-311
25. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope. 1988;98(11):1205-1211.
26. Harper E, Dang W, Lapidus RG, Garver RI Jr. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res. 1999 5(12):4242-4248
27. Lapidus RG, Dang W, Rosen DM, etal. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation. Prostate. 2004;58(3):291-298
28. XieM,Zhou L, HuT, YaoM. Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts. Anticancer Drugs. 2007;18(4):459-466.
29. WernerS, Grose R. Regulation of wound healing by growth factors and cytokines Physiol Rev. 2003;83(3):835-870.
30. Arias JI, Aller MA, Arias J. The use of inflammation by tumor cells. Cancer. 2005; 104(2):223-228
31. Kortlever RM, Bernards R. Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle. 2006;5(23):2697-2703
32. Matsumoto K, NakamuraT. Hepatocyte growth factorand the Met system as a mediator of tumor-stromal interactions. Int J Cancer. 2006;119(3):477-483
33. Yoo GH, Subramanian G, Boinpally RR, etal. An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma [published correction appears in Arch Otolaryngol Head Neck Surg. 2006;132(11):1188]. Arch Otolaryngol Head Neck Surg. 2005;131(5):418-429
34. Yoo GH, Lin HS, IskanderAJ, etal. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study. Laryngoscope. 2005;115(11):1938-1946.
35. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989;246(4929):491-494
36. Yamori T, Sato S, Chikazawa H, Kadota T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res. 1997;88(12):1205-1210
37. Han EK, Gehrke L,TahirSK, etal. Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell lines [published correction appears in Eur J Cancer. 2007;43(6):1108]. Eur J Cancer. 2000;36(12):1565-1571.
38. Piechocki MP, Lonardo F, Ensley JF, Nguyen T, Kim H, Yoo GH. Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin Cancer Res. 2002; 8(3):870-877
39. Scappaticci FA, Fehrenbacher L, CartwrightT, etal. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab J Surg Oncol. 2005;91(3):173-180
40. YooGH, Piechocki MP, Oliver J, etal. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope. 2004;114(11):1871-1879
41. Theon AP, Pascoe JR, Meagher DM. Perioperative intratumoral administration of cisplatin for treatment of cutaneous tumors in equidae. J Am Vet Med Assoc. 1994;205(8):1170-1176
42. Spugnini EP, Baldi A, Vincenzi B, et al. Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol. 2007;59(3):375-381
43. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res. 2002;105(1):43-47
44. Myoung H, Hong SD, Kim YY, Hong SP, Kim MJ. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotrans-planted oral squamous cell carcinoma. Cancer Lett. 2001;163(2):191-200